Form 4 for MNKD MANNKIND CORP
Accepted 2023-05-26 00:00:00 ET · period of report 2023-05-25 · accession 0001209191-23-032728 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-05-26 | 2023-05-25 | MNKD | Thomson David | EVP Genl Counsel, Sec | A - Grant | $0.00 | +92.0K | 827.3K | +13% | $0 |
| D | 2023-05-26 | 2023-05-25 | MNKD | Thomson David | EVP Genl Counsel, Sec | A - Grant | $0.00 | +113.0K | 113.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, $.01 Par Value | 2023-05-25 | A | A | 92,000 | $0.00 | 827,263 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. (F2) Acquired pursuant to a Restricted Stock Unit Award: 25% vests on July 15, 2024 and each yearly anniversary thereof until fully vested. |
| 2 | Derivative | Performance Restricted Stock Unit | 2023-05-25 | A | A | 113,000 | $0.00 | 113,000 | D | — · — to — | 113,000 Common Stock, $.01 Par Value | (F1) Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. (F3) The performance-based restricted stock unit will vest on July 15, 2026, provided that the closing price of MannKind common stock on the Nasdaq Global Market on June 30, 2026 is not less than the closing sale price on July 1, 2023. The number of shares delivered on the vesting date, as a percentage of the target specified in Table II Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2023 until June 30, 2026 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. |